SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in conversation as a self-described Bitcoin parody that leans into its origins as an early 2011 internet joke to differentiate itself from newer meme coins. The community is actively debating its potential as a 'next-gen' asset, highlighting its long-standing lore and historical ties to the broader crypto ecosystem while dismissing recent unrelated copycats as scams.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently generating significant market conversation following a Canary Capital ETF filing that has renewed institutional interest and fueled community speculation about a potential major upward move. Investors are actively debating the token's long-term meme status versus its utility as a blue-chip asset, with many focusing on its price action as a key indicator of broader altcoin market health and potential rotation from Bitcoin.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant momentum and social media buzz as participants speculate on potential major corporate partnerships and celebrate the project's real-world utility in the decentralized events sector. The community is actively debating the token's explosive price action, with some focused on long-term growth and others cautioning about high volatility and potential profit-taking.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a focal point for investors as they anticipate a transformative FDA Biologics License Application (BLA) decision for their lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is intensely focused on the company's clinical pipeline, with active discussions centering on the upcoming interim progression-free survival data and the broader competitive threat the drug poses to existing blockbuster immunotherapies.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is capturing market attention as the bank navigates a complex environment of shifting private credit regulations and internal loan markdowns, while analysts closely monitor its role in major upcoming IPOs and the broader impact of AI-driven cyber threats on the financial sector. The community is actively debating the bank's defensive positioning and potential earnings strength, with traders specifically focused on its institutional options activity and price action relative to key sector support levels.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is currently drawing significant attention from investors as it hits fresh 52-week highs, driven by a combination of successful strategic divestitures in markets like Russia and Mexico and growing market optimism surrounding its long-term profitability overhaul. Traders are actively debating the sustainability of this recent rally, closely monitoring upcoming earnings as a potential catalyst while reacting to regulatory developments that are viewed as a positive signal for the bank's operational flexibility.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors digest news of its integration into BMW's upcoming vehicle line, sparking renewed focus on QNX's role as a foundational software layer for software-defined vehicles. Community sentiment remains polarized, with many retail holders maintaining long-term conviction in QNX's growth potential despite ongoing price volatility and frustrations over recent stock performance.

Maulcoin

Maulcoin is trending as its community aggressively pushes for a break into 'penny land,' fueled by excitement over potential airdrops and expectations of an upcoming chart listing. Supporters are actively rallying on social media to build momentum, framing the project as a long-term, community-driven alternative to typical meme coin pump-and-dump schemes.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Akoustis Technologies Inc

Akoustis Technologies has completed the sale of its assets to a subsidiary of SpaceX, formally concluding its Chapter 11 bankruptcy process. The community is actively discussing the impact of this liquidation, with many shareholders expressing that their equity positions have been wiped out following the finalization of the sale.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is garnering attention as a core infrastructure play within the AI-Crypto narrative, with the community highlighting its deflationary mechanics and integration with AI-Intents technology as long-term catalysts. Despite recent price volatility, investors are actively discussing the protocol's developer traction and its potential for relative outperformance as capital rotates into high-beta ecosystems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Opus Genetics (NASDAQ:IRD) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on Opus Genetics in a report on Monday. They set an "overweight" rating and a $15.00 price target on the stock...

Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Grows By 81.3%

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 2,014,121 shares, an increase of 81.3% from the February 26th total of 1,110,696 shares. Based on an average daily trading...

Opus Genetics (IRD) to Release Earnings on Monday

Opus Genetics (NASDAQ:IRD) will be releasing earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-opus-genetics-inc-stock...

Opus Genetics (NASDAQ:IRD) Insider Rabourn Amy Zaremba Sells 2,816 Shares

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) insider Rabourn Amy Zaremba sold 2,816 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average...

Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells 2,816 Shares of Stock

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) insider Rabourn Amy Zaremba sold 2,816 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at...

Insider Selling: Opus Genetics (NASDAQ:IRD) Insider Sells $19,041.28 in Stock

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) insider Ashwath Jayagopal sold 3,719 shares of Opus Genetics stock in a transaction on Monday, March 16th. The shares were sold at an average price...

Joseph Schachle Sells 3,719 Shares of Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) COO Joseph Schachle sold 3,719 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of...

Insider Selling: Opus Genetics (NASDAQ:IRD) CEO Sells 24,438 Shares of Stock

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) CEO George Magrath sold 24,438 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $5.21, for a...

Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Up 17.9% in February

Opus Genetics, Inc. (NASDAQ:IRD - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 1,110,696...

Oppenheimer Initiates Coverage on Opus Genetics (NASDAQ:IRD)

Oppenheimer began coverage on shares of Opus Genetics in a report on Monday. They set an "outperform" rating and a $10.00 price target for the company...

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

IRD
Opus Genetics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest IRD News

IRDOpus Genetics Inc.